Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
24.97
-0.19 (-0.76%)
At close: Dec 26, 2025, 4:00 PM EST
24.82
-0.15 (-0.60%)
After-hours: Dec 26, 2025, 5:00 PM EST
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 19 analysts that cover Apellis Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $33.89, which forecasts a 35.72% increase in the stock price over the next year. The lowest target is $18 and the highest is $52.
Price Target: $33.89 (+35.72%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 4 | 4 | 5 |
| Buy | 6 | 7 | 7 | 7 | 7 | 6 |
| Hold | 9 | 10 | 9 | 8 | 9 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Total | 19 | 20 | 20 | 20 | 21 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $55 → $48 | Strong Buy | Maintains | $55 → $48 | +92.23% | Dec 19, 2025 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $40 → $36 | Buy | Maintains | $40 → $36 | +44.17% | Nov 5, 2025 |
| Mizuho | Mizuho | Hold Maintains $24 → $19 | Hold | Maintains | $24 → $19 | -23.91% | Nov 3, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $52 → $45 | Strong Buy | Maintains | $52 → $45 | +80.22% | Oct 31, 2025 |
Financial Forecast
Revenue This Year
1.01B
from 781.37M
Increased by 28.88%
Revenue Next Year
885.70M
from 1.01B
Decreased by -12.05%
EPS This Year
0.25
from -1.60
EPS Next Year
-1.11
from 0.25
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.0B | ||||
| Avg | 1.0B | 885.7M | ||||
| Low | 684.3M | 771.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 41.2% | -0.4% | ||||
| Avg | 28.9% | -12.0% | ||||
| Low | -12.4% | -23.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.50 | 0.44 | ||||
| Avg | 0.25 | -1.11 | ||||
| Low | 0.13 | -1.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 80.5% | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.